Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

How to open an account

Bell Direct
September 1, 2015

Beston Global Food Company Interview

Bell Direct
August 28, 2015

Bell Direct Insights: Richard Hemming

Bell Direct
August 24, 2015

Bell Potter video: Bank sector update

Bell Direct
August 14, 2015

Agricultural Sector Review

Bell Direct
August 3, 2015

Peter Quinton: three REITs

Bell Direct
July 23, 2015

Contango CIO interview

Bell Direct
July 17, 2015

Julia Lee on mFunds

Bell Direct
July 6, 2015